Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 1Insulin Resistance 1Inflammation 1Hyperandrogenism 1Anovulation 1

Interventions

pembrolizumab 1282Specimen Handling 927Carboplatin 836Magnetic Resonance Spectroscopy 834Cyclophosphamide 807Cisplatin 735Nivolumab 680Paclitaxel 635Radiotherapy 617Gemcitabine 580Biopsy 559Bevacizumab 485Dexamethasone 444fludarabine 410Docetaxel 385venetoclax 372Oxaliplatin 367Capecitabine 361Fluorouracil 357atezolizumab 350durvalumab 340Rituximab 335Drug Therapy 333Radiosurgery 321Doxorubicin 319Blood Specimen Collection 317Standard of Care 311Pemetrexed 307Ipilimumab 303Radiation 287

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
salicylsalicylic acid × 1 year × Clear all
NCT03229408 2025-06-10

TIN-PCOS-AOD

University of Illinois at Chicago

Phase 2 Completed
60 enrolled 28 charts

Anovulation, Inflammation, Insulin Resistance, Polycystic Ovary Syndrome, Hyperandrogenism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡